On May 12, 2022, the Securities and Exchange Commission ("SEC") announced that it has acquired Aurora Cannabis Inc., a Canadian-based medical cannabis company.  The SEC's complaint, filed in federal court in Canada, alleges that Aurora was unable to generate sufficient revenue to meet its $150 million annualized sales target.  According to the SEC's complaint, Aurora was unable to generate sufficient revenue to meet the $150 million annualized sales target.  The SEC's complaint, filed in the U.S. District Court for the District of Columbia, alleges that Aurora was unable to meet its $150 million annualized revenue target.  According to the complaint, Aurora was unable to meet the $150 million target because of capacity constraints.  The SEC's complaint, filed in U.S. District Court in the District of Columbia, alleges that Aurora failed to meet the $150 million target.  The SEC's complaint charges that Aurora failed to meet its $150 million target.  The complaint alleges that Aurora failed to meet its $150 million annualized sales goal.  The SEC's complaint charges that Aurora violated the antifraud provisions of Section 17(a) of the Securities Act of 1933 ("Securities Act") and Section 10(b) of the Securities Exchange Act of 1934 ("Exchange Act") and Rule 10b-5 thereunder.  Without admitting or denying the allegations in the SEC's complaint, Aurora has consented to the entry of a final judgment that permanently enjoins it from violating the antifraud provisions of Sections 17(a)(1) and (3) of the Securities Act and Section 10(b) of the Exchange Act and Rules 10b-5(a) and (c) thereunder.  The settlement is subject to court approval.  The SEC's investigation, which is continuing, is being conducted by Andrew Carter, Victor Ma, and John Zamparo of the SEC's Philadelphia Regional Office.  The SEC appreciates the assistance of the U.S. Attorney's Office for the District of Columbia, the Federal Bureau of Investigation, and the Financial Industry Regulatory Authority.